Greg J Goodman1, Stefania Roberts2, Peter Callan3. 1. Skin and Cancer Foundation Inc. and Monash University, Wellington Rd, Clayton, VIC, 3168, Australia. jacqui@div.net.au. 2. Dermatology Institute of Victoria, South Yarra, Australia. 3. Private Practice, Geelong, VIC, Australia.
Abstract
BACKGROUND: Intravascular injection leading to skin necrosis or blindness is the most serious complication of facial injection with fillers. It may be underreported and the outcome of cases are unclear. Early recognitions of the symptoms and signs may facilitate prompt treatment if it does occur avoiding the potential sequelae of intravascular injection. OBJECTIVES: To determine the frequency of intravascular injection among experienced injectors, the outcomes of these intravascular events, and the management strategies. METHODS: An internet-based survey was sent to 127 injectors worldwide who act as trainers for dermal fillers globally. RESULTS: Of the 52 respondents from 16 countries, 71 % had ≥11 years of injection experience, and 62 % reported one or more intravascular injections. The most frequent initial signs were minor livedo (63 % of cases), pallor (41 %), and symptoms of pain (37 %). Mildness/absence of pain was a feature of 47 % of events. Hyaluronidase (5 to >500 U) was used immediately on diagnosis to treat 86 % of cases. The most commonly affected areas were the nasolabial fold and nose (39 % each). Of all the cases, only 7 % suffered moderate scarring requiring surface treatments. Uneventful healing was the usual outcome, with 86 % being resolved within 14 days. CONCLUSION: Intravascular injection with fillers can occur even at the hands of experienced injectors. It may not be always associated with immediate pain or other classical symptoms and signs. Prompt effective management leads to favorable outcomes, and will prevent catastrophic consequences such as skin necrosis. Intravascular injection leading to blindness may not be salvageable and needs further study. LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
BACKGROUND: Intravascular injection leading to skin necrosis or blindness is the most serious complication of facial injection with fillers. It may be underreported and the outcome of cases are unclear. Early recognitions of the symptoms and signs may facilitate prompt treatment if it does occur avoiding the potential sequelae of intravascular injection. OBJECTIVES: To determine the frequency of intravascular injection among experienced injectors, the outcomes of these intravascular events, and the management strategies. METHODS: An internet-based survey was sent to 127 injectors worldwide who act as trainers for dermal fillers globally. RESULTS: Of the 52 respondents from 16 countries, 71 % had ≥11 years of injection experience, and 62 % reported one or more intravascular injections. The most frequent initial signs were minor livedo (63 % of cases), pallor (41 %), and symptoms of pain (37 %). Mildness/absence of pain was a feature of 47 % of events. Hyaluronidase (5 to >500 U) was used immediately on diagnosis to treat 86 % of cases. The most commonly affected areas were the nasolabial fold and nose (39 % each). Of all the cases, only 7 % suffered moderate scarring requiring surface treatments. Uneventful healing was the usual outcome, with 86 % being resolved within 14 days. CONCLUSION: Intravascular injection with fillers can occur even at the hands of experienced injectors. It may not be always associated with immediate pain or other classical symptoms and signs. Prompt effective management leads to favorable outcomes, and will prevent catastrophic consequences such as skin necrosis. Intravascular injection leading to blindness may not be salvageable and needs further study. LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Authors: Fernando Urdiales-Gálvez; Nuria Escoda Delgado; Vitor Figueiredo; José V Lajo-Plaza; Mar Mira; Antonio Moreno; Francisco Ortíz-Martí; Rosa Del Rio-Reyes; Nazaret Romero-Álvarez; Sofía Ruiz Del Cueto; María A Segurado; Cristina Villanueva Rebenaque Journal: Aesthetic Plast Surg Date: 2018-01-05 Impact factor: 2.326
Authors: Tomasz Stefura; Artur Kacprzyk; Jakub Droś; Marta Krzysztofik; Oksana Skomarovska; Marta Fijałkowska; Mateusz Koziej Journal: Aesthetic Plast Surg Date: 2021-07-13 Impact factor: 2.708
Authors: Marc Mespreuve; Karl Waked; Barbara Collard; Joris De Ranter; Francis Vanneste; Benoit Hendrickx Journal: Aesthet Surg J Open Forum Date: 2021-05-11